SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: Rich R who wrote (439)12/21/1998 11:37:00 AM
From: Loren  Respond to of 675
 
Is this info. from the conference?



To: Rich R who wrote (439)12/21/1998 3:27:00 PM
From: molemania  Read Replies (1) | Respond to of 675
 
Rich - You are talking about $1.46 per share over 5 to 6 years IF everything goes exactly right in all clinical trials. Many great companies (Syntex, Chiron, etc.) have attempted an MS drug and failed. And of course the royalties kick in only if the drug is approved by the FDA more than 5 years from now.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News